Medications for Opioid Use Disorder in Residential Treatment: Buprenorphine, Naltrexone, and What to Expect

Most people who come to residential treatment for opioid use disorder have already tried to stop on their own, often many times. They know the arc by heart: a rough first night, two days of bone aches and cold sweats, then a third day when the only thought still functioning is the one about relief. The return to use that follows rarely feels like a decision.

What many people have never been told is that medication can change the shape of that arc, and that starting it under medical supervision inside a structured program is nothing like trying to manage it alone. Medications for opioid use disorder, sometimes shortened to MOUD or MAT, come up in nearly every admissions call we take, and they remain among the most misunderstood parts of addiction care.

What MOUD Is, and What It Is Not

Three medications are approved in the United States for opioid use disorder: buprenorphine (often dispensed in combination with naloxone), naltrexone, and methadone. They work in very different ways. Buprenorphine and methadone occupy the same receptors that opioids do, which quiets withdrawal and craving without producing the same intensity of effect. Naltrexone does the opposite, blocking those receptors so that opioids produce little or nothing.

Both the National Institute on Drug Abuse and the Substance Abuse and Mental Health Services Administration describe these medications as evidence-based treatment for opioid use disorder, not as a lesser alternative to abstinence-based care. That framing matters, because the objection we hear most often is some version of trading one addiction for another. The concern deserves a real answer rather than a dismissal. Physical dependence and addiction are not the same thing. A prescribed, stable dose that does not produce intoxication, does not escalate, and does not organize a person’s whole day around obtaining it looks nothing like the pattern that brought them to treatment. Many people describe the difference simply: the noise stops.

The First Week on Buprenorphine

The most counterintuitive part of starting buprenorphine is that a person needs to be in withdrawal before the first dose. Because buprenorphine binds tightly to opioid receptors, taking it while other opioids are still present can displace them abruptly and set off precipitated withdrawal, which is worse than what the person walked in with. So clinical staff wait, and they measure. Withdrawal is scored on a structured scale, and the specific signs matter: gooseflesh on the forearms, pupils widening, yawning that will not stop, restless legs that make sitting through a group impossible.

When the timing is right, the first dose often works quickly. People frequently describe something settling within half an hour to an hour, and the description tends to be understated rather than dramatic. The aches back off. The sweating stops. Someone who could not sit still for ten minutes eats a full meal that afternoon.

The following days are less about relief and more about calibration. Doses are adjusted, sometimes several times, until cravings are quiet and the person is not sedated. Constipation is common and gets treated. Sleep is usually the last thing to come back, and it may take weeks rather than days. This is one reason a residential setting helps: adjustments happen with a nurse in the building rather than at an appointment two weeks out. Potent fentanyl analogs in the drug supply have also made induction less predictable, and some people need a longer waiting window or a modified approach. That is a clinical judgment call, not something to attempt at home.

Naltrexone: A Longer Runway, a Different Decision

Naltrexone appeals to people who want no opioid in their system at all, and for some it is the right fit. The obstacle is the gap it requires. Because naltrexone blocks receptors, it cannot be started until a person has been off opioids long enough to clear them, commonly a week or more depending on what was used, and starting too early can trigger significant withdrawal. Very few people can hold that gap open by themselves. A residential stay is often what makes it possible at all.

Naltrexone does not relieve withdrawal, so the days before the first dose are managed with supportive medications for nausea, muscle aches, anxiety, and sleep. Once it is in place, usually as a monthly extended-release injection, people tend to report that cravings are quieter and less interesting. The thought still arrives; it just has less pull. Liver function is monitored, and anyone with significant pain problems needs a plan in advance, since standard opioid pain control will not work normally while the medication is active.

Methadone, and Why Access Looks Different

Methadone remains an effective option, particularly for people with long histories of high-dose use, but it is dispensed through federally regulated opioid treatment programs rather than prescribed like other medications. In practice that means coordination: a residential program works with a licensed opioid treatment program for dosing, and the discharge plan has to include a receiving clinic before the person leaves. When someone arrives already stable on methadone, the goal is continuity. Stopping an established dose because a person changed levels of care is a preventable setback.

Sorting out which option fits your situation, or a family member’s, is a conversation worth having with clinicians rather than the internet. You can reach our admissions team at (877) 328-1968.

What Families Notice in the First Month

Families often expect medication to produce a visible transformation and are unsettled when week one sounds flat instead. Phone calls are short. The person sounds tired, sometimes irritable, not especially grateful. That is usually what stabilization looks like from the outside, not a sign of failure. Affect returns in the second and third weeks, in small ways: a joke on the phone, a question about someone else’s life, an actual opinion about dinner.

The other thing families raise is the fear that medication is a loophole, a way to feel better without changing anything. The honest answer is that medication makes change possible without guaranteeing it. It reduces the physiological pressure that makes therapy, accountability, and rebuilt routines nearly impossible to sustain. It does not do those things on its own, and no clinician should promise that it will.

Medication Is One Part of the Day, Not the Whole Plan

Inside residential treatment, the medication visit is a small part of the schedule. The rest is individual therapy, process groups, relapse-prevention skills, work on trauma when a person is stable enough for it, family sessions, and case management aimed at the practical wreckage: employment, housing, court dates, custody. The American Society of Addiction Medicine frames medication as one component within a level of care matched to a person’s overall needs, and that is roughly how it feels from the inside. Medication makes the day workable. The day is where the change happens.

Length of stay is matched to the person rather than a fixed template, and most plans step down rather than stop. An outpatient program with continued medication management is a far more durable ending than a discharge date and a phone number.

Safety Issues Worth Saying Plainly

Three points deserve emphasis. First, tolerance drops fast during any period away from opioids, which means that a return to a previously familiar amount can be fatal. Anyone leaving treatment, and their family, should have naloxone on hand and know how to use it. This is not a statement of expectation; it is basic preparation.

Second, opioid use rarely travels alone. Many people are also using alcohol, benzodiazepines, or both. Withdrawal from alcohol and from benzodiazepines can cause seizures and delirium and can be life-threatening, unlike opioid withdrawal, which is agonizing but not usually dangerous in itself. Those withdrawals require medical supervision and a structured taper. Nobody should attempt them alone or on a self-designed schedule, and a program needs to know about every substance involved before detox begins.

Third, stimulant use alongside opioids is increasingly common, and there is no approved medication for stimulant use disorder, so that side of the plan relies on behavioral treatment. Say what you are actually using at intake. Accurate information is what makes a safe plan possible.

Where to Start

There is no single correct medication. The decision is a shared one, shaped by history, other medical conditions, pain, prior attempts, and what a person is willing to sustain. It also does not need to be settled before anyone asks for help. Most people work it out in the first days of care, with a physician in the room.

If cost is what is holding you back, you can verify your insurance benefits before committing to anything, or call (877) 328-1968 and ask. It is a short conversation and it costs nothing.

This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Decisions about medications for opioid use disorder should be made with a qualified healthcare professional who knows your history. Withdrawal from alcohol or benzodiazepines can be medically dangerous and requires supervision. If you are experiencing a medical emergency, call 911.